Can pharmacokinetic/pharmacodynamic targets be achieved with voriconazole in the treatment of urinary tract infections caused by Candida spp. with reduced susceptibility to fluconazole?
Journal of Antimicrobial Chemotherapy · 02.07.2026 · 81 (8)
DOI: 10.1093/jac/dkag231 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 22.07.2026. Verfasst von Christelle Boglione-Kerrien und 11 weiteren Autor:innen. Beteiligte Einrichtung: CHU Rennes, Laboratory of Biological Pharmacology, Rennes, France. Hauptthemen laut MEDLINE: Voriconazole, Antifungal Agents, Urinary Tract Infections, Candida. Die Arbeit nennt 47 Literaturangaben. Gefördert von: French Society of Medical Mycology (SFMM), French Society of Pharmacology and Therapeutics (SFPT).
Abstract (Originalsprache)
Background
Treating Candida spp. urinary tract infections (UTIs) are challenging when isolates have reduced susceptibility to fluconazole. Voriconazole may be a therapeutic alternative despite its low urinary excretion as an unchanged compound.
Objectives
To quantify voriconazole and its main metabolite, voriconazole N-oxide, in urine and plasma, determine minimum inhibitory concentrations (MICs) of voriconazole and voriconazole N-oxide, and assess the antifungal activity of urine from voriconazole-treated patients.
Methods
Sixty patients receiving oral voriconazole were prospectively included. Voriconazole and voriconazole N-oxide concentrations in urine (12-h urine volume) and plasma were measured by liquid chromatography-tandem mass spectrometry. MICs were determined by broth microdilution according to EUCAST guidelines. Urinary antifungal activity was assessed using a disk diffusion bioassay, including against N. glabratus. A pharmacokinetic/pharmacodynamic target concentration/MIC >1 in urine was defined.
Results
Median voriconazole urinary concentration was 1.9 mg/L [1.1–3.1], similar to plasma trough concentration (2.2 mg/L) and positively correlated (R2 = 0.82). Voriconazole N-oxide urinary concentrations (median 20.4 mg/L) were substantially higher than plasma trough concentrations (median 2.1 mg/L). Voriconazole MICs ranged from 0.155 to 0.75 mg/L, while voriconazole N-oxide MICs were 32–48 mg/L for reduced susceptibility to fluconazole isolates. Urine with voriconazole concentrations above 3 mg/L was more likely to inhibit N. glabratus. The median urinary voriconazole concentration/MIC ratio of 4.75 supports potential clinical efficacy.
Conclusions
Voriconazole can achieve therapeutically relevant urinary concentrations for treating UTIs with reduced susceptibility to fluconazole. Therapeutic drug monitoring may facilitate individualized dosing and optimize treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- CHU Rennes, Laboratory of Biological Pharmacology, Rennes, France.
- Univ Rennes, CHU de Rennes, Inserm, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France.
- Univ. Grenoble Alpes, INSERM U1300, HP2 Laboratory, Grenoble, France.
- Univ. Grenoble Alpes, CHU Grenoble Alpes, Laboratoire de Pharmacologie, Pharmacogénétique et Toxicologie, Grenoble, France.
- Pharmacokinetics and Toxicology Laboratory, Federative Institute of Biology, Toulouse University Hospital, Toulouse, France.
- INTHERES, University of Toulouse, INRAE, ENVT, Toulouse, France.
ORCID-Profile: Christelle Boglione-Kerrien, Florian Lemaitre, Elodie Gautier-Veyret, Marie-Clémence Verdier, Jean-Pierre Gangneux
Förderung
- French Society of Medical Mycology (SFMM)
- French Society of Pharmacology and Therapeutics (SFPT)
Zitieren
APA
Boglione-Kerrien, C., Lemaitre, F., Gautier-Veyret, E., Baklouti, S., Hulin, A., Cornet, M., Botterel, F., Morcet, J., Le Bot, A., Verdier, M. C., Gangneux, J. P., & Guegan, H. (2026). Can pharmacokinetic/pharmacodynamic targets be achieved with voriconazole in the treatment of urinary tract infections caused by Candida spp. with reduced susceptibility to fluconazole?. Journal of Antimicrobial Chemotherapy, 81(8). https://doi.org/10.1093/jac/dkag231
Vancouver
Boglione-Kerrien C, Lemaitre F, Gautier-Veyret E, Baklouti S, Hulin A, Cornet M, et al. Can pharmacokinetic/pharmacodynamic targets be achieved with voriconazole in the treatment of urinary tract infections caused by Candida spp. with reduced susceptibility to fluconazole?. Journal of Antimicrobial Chemotherapy. 2026;81(8). doi:10.1093/jac/dkag231
BibTeX
@article{BoglioneKerrien2026,
author = {Boglione-Kerrien, Christelle and Lemaitre, Florian and Gautier-Veyret, Elodie and Baklouti, Sarah and Hulin, Anne and Cornet, Muriel and Botterel, Françoise and Morcet, Jeff and Le Bot, Audrey and Verdier, Marie-Clémence and Gangneux, Jean-Pierre and Guegan, Hélène},
title = {Can pharmacokinetic/pharmacodynamic targets be achieved with voriconazole in the treatment of urinary tract infections caused by Candida spp. with reduced susceptibility to fluconazole?},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
volume = {81},
number = {8},
doi = {10.1093/jac/dkag231}
}
EUVIMED